<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197115</url>
  </required_header>
  <id_info>
    <org_study_id>F-2019-506-010</org_study_id>
    <nct_id>NCT04197115</nct_id>
  </id_info>
  <brief_title>Vitamin C, Thiamine, Cyanocobalamine, Pyridoxine and Hydrocortisone in Sepsis</brief_title>
  <official_title>Difference in Mortality and Evolution in Septic Patients Treated With Vitamin C, Tiamine, Cyanocobalamine, Pyridoxine and Hydrocortisone Treated at the ICU of General Hospital Zone 11 IMSS Piedras Negras Coahuila.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IMSS Hospital General de Zona 11, Piedras Negras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IMSS Hospital General de Zona 11, Piedras Negras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, experimental, longitudinal cohort study in septic patients treated at ER and ICU
      at General Hospital Zone 11 IMSS Piedras Negras Coahuila.

      Interventions, will be implementd in 2 consecutive periods of 6 months Phase 1: 6 months
      period, septic patients treated only with standard treatment.

      Phase 2: 6 months period, septic patients treated with Vitamin C, Thiamine, Cyanocobalamine,
      Pyridoxine and Hydrocortisone + standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research protocol will consist of two phases:

      Phase 1: collection of statistical data of septic patients in whom standard treatment will be
      applied according to clinical practice guidelines, with an approximate duration of 6 months

      Phase 2: experimental period lasting 6 months in which the standard treatment will be applied
      according to clinical practice guidelines + the treatment protocol consisting of Vitamin C
      1.5 g IV every 6 hours, Hydrocortisone 50 mg IV every 6 hours and in case of having Enteral
      route Complex B (Thiamine 100 mg, Pyridoxine 5 mg, Cyanocobalamin 50 mcg) 1 tablet every 6
      hours for 4 continuous days or until discharge from the ICU patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Prospective longitunal experimental</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in hospital mortality in phase 1 vs phase 2 groups</measure>
    <time_frame>1 year</time_frame>
    <description>Quantitative variable: Metric unit: number (percentage); Mortality in hospital</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Intensive Care Unit Mortality in phase 1 vs phase 2 groups</measure>
    <time_frame>1 year</time_frame>
    <description>Quantitative variable; Metric unit: number (percentage); Mortality in Intensive Care Unit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in SOFA (Sequential Organ Failure Assessment) between phase 1 vs phase 2 groups</measure>
    <time_frame>1 year</time_frame>
    <description>Quantitative variable: Maximal score of SOFA (Sequential Organ Failure Assessment) will be recorded; Value range 0-24 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in number of days with vasopressor use between phase 1 vs phase 2 groups.</measure>
    <time_frame>1 year</time_frame>
    <description>Quantitative variable; Metric unit: number of days with vasopressors; Vasopressors defined as use of at leas one or in addition of epinephrine, norepinephrine, dobutamine, dopamine, vasopressin.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Septic patients admited to ICU whick will be treated as specified in current guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Septic patients admitted to ICU which will be treated as specified in current guidelines adding:
Vitamin C Hydrocortisone B complex (Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.</description>
    <arm_group_label>Phase 2</arm_group_label>
    <other_name>ascorbic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.</description>
    <arm_group_label>Phase 2</arm_group_label>
    <other_name>Hydrocortisone sodium succinate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Complex B</intervention_name>
    <description>Complex B ((Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg) 1 tablet enteral route every 6 horas for 4 days or until ICU discharge</description>
    <arm_group_label>Phase 2</arm_group_label>
    <other_name>vitamin B complex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected or confirmed infection as evidenced by ordering of blood cultures and
             administration of at least one antimicrobial agent

          -  Acute respiratory or cardiovascular organ dysfunction attributed to sepsis as
             evidenced by at least one of the following requirements:

          -  Vasopressor Requirement - Continuous infusion of norepinephrine, epinephrine,
             vasopressin, dopamine, phenylephrine or other vasopressor agents at any dose for
             greater than 1 hour and required to maintain a mean arterial pressure ≥ 65 mm Hg
             despite intravenous crystalloid infusion of at least 1000cc

          -  Respiratory Support Requirement - Acute hypoxemic respiratory failure defined as
             persistent hypoxemia ( partial pressure of arterial oxygen (PaO2)/fraction of inspired
             oxygen (FiO2) ≤ 300 or blood oxygen saturation (SpO2)/FiO2 ≤ 315) requiring (1)
             intubation and mechanical ventilation, or (2) positive pressure ventilation via tight-
             fitting f ace mask (i.e. continuous positive airway pressure (CPAP) or bilevel
             positive airway pressure (BiPAP) or (3) high flow nasal cannula ≥ 45 liter per minute
             (LPM) flow and FiO2

               -  0.40

          -  Anticipated or confirmed intensive care unit (ICU) admission

        Exclusion Criteria:

          -  Organ dysfunction present &gt; 24 hours at time of enrollment

          -  Limitations of care (defined as refusal of cardiovascular and respiratory support
             modes described in inclusion criteria 7.1.b) including &quot;do not intubate&quot; (DNI) status

          -  Current hospitalization &gt; 30 days at time of randomization

          -  Chronic hypoxemia requiring supplemental non-invasive oxygen (nasal cannula or NIPPV)
             or home mechanical ventilation

          -  Chronic cardiovascular failure requiring home mechanical hemodynamic support (e.g.,
             LVAD) or home chemical hemodynamic support (e.g., milrinone)

          -  Known allergy or contraindication to vitamin C, thiamine, and/or corticosteroids
             (including previously or currently diagnosed primary hyperoxaluria and/or oxalate
             nephropathy, or nown/suspected ethylene glycol ingestion, or known glucose-6-phosphate
             dehydrogenase (G6PD) deficiency)

          -  Currently receiving intravenous vitamin C as a treatment for sepsis OR any dose of
             vitamin C exceeding 1 gram daily

          -  Chronic disease/illness that, in the opinion of the site investigator, have an
             expected lifespan of &lt; 30 days unrelated to current sepsis diagnosis (e.g., stage IV
             malignancy, neurodegenerative disease, etc.)

          -  Pregnancy or known active breastfeeding

          -  Prisoner or Incarceration

          -  Current participation in another interventional pharmaceutical research study for
             sepsis Inability or unwillingness of subject or legal surrogate/representative to give
             written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JOSE IVAN RODRIGUEZ DE MOLINA SERRANO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMSS HGZ 11 UTI PIEDRAS NEGRAS COAHUILA MEXICO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JOSE IVAN RODRIGUEZ DE MOLINA SERRANO, M.D.</last_name>
    <phone>5525848735</phone>
    <email>jirdems@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HUGO HUMBERTO CASTRO, NURSE</last_name>
    <phone>878 1174687</phone>
    <email>hugo_c4stro@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Zona 11 Imss Piedras Negras Coahuila</name>
      <address>
        <city>Piedras Negras</city>
        <state>Coahuila</state>
        <zip>26020</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JOSE IVAN RODRIGUEZ DE MOLINA SERRAN, PH</last_name>
      <phone>52552584735</phone>
      <email>jirdems@gmail.com</email>
    </contact>
    <investigator>
      <last_name>JOSE IVAN RODRIGUEZ DE MOLINA SERRANO, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>HUGO HUMBERTO CASTRO MARTINEZ, NURSE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IMSS Hospital General de Zona 11, Piedras Negras</investigator_affiliation>
    <investigator_full_name>JOSE IVAN RODRIGUEZ DE MOLINA SERRANO</investigator_full_name>
    <investigator_title>Head of Intensive Care Unit Jose Ivan RodriguezdeMolina Critical Care Ph.</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>septic shock</keyword>
  <keyword>Vitamin C</keyword>
  <keyword>Hydrocortisone</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

